UCB Ventures is a €150 million strategic corporate venture fund. The firm is interested in early-stage ventures, and has been in operations since 2017.
The firm looks to create value by providing novel insights and technologies that can transform the lives of patients that suffer from severe diseases. The diseases the fund aims to defeat include neurological diseases and muscular skeletal/bone. UCB Ventures looks to invest in companies such as MyHealthTeams, Locana, Rinri Therapeutics, and invests during seed and early Series rounds.
StrideBio, Inc. is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies.
Walden Biosciences is a Cambridge, Massachusetts-based company.